Kozulin Nikita, Migulina Anastasiya, Mokrushin Denis, Soghoyan Gurgen, Artemenko Aleksandr, Biktimirov Artur
Laboratory of Experimental and Translational Medicine, School of Medicine and Life Sciences, Far Eastern Federal University, Vladivostok, Russia.
Vladimir Zelman Center for Neurobiology and Brain Rehabilitation, Skolkovo Institute of Science and Technology, Moscow, Russia.
Heliyon. 2024 Oct 5;10(20):e39014. doi: 10.1016/j.heliyon.2024.e39014. eCollection 2024 Oct 30.
Parkinson's disease (PD) is a common neurodegenerative disease characterized by rest tremor, rigidity, and bradykinesia. Assessing the severity of these symptoms is typically done using the third part of the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS III), relying on subjective evaluations by neurologists, which may lead to challenges in result interpretation. To address this issue, incorporation of surface electromyography (sEMG) in diagnostics.
The aim of the study is to search for specific sEMG patterns that allow assessing the severity of bradykinesia.
This case-control study involved 8 patients with PD at Hoehn & Yahr stages 2-3, and 7 healthy volunteers. sEMG was measured while the subjects performed the "finger tapping" and "hand movements" tests of the MDS-UPDRS III. The tests were conducted both before and after levodopa intake to identify patterns indicating changes in motor functions. During the tests, we observed the peak activity of the sEMG signal, reflecting the moments of activation of individual muscle groups involved in the implementation of the movement. Peak activity was characterized by the total number of maximum sEMG signal extrema and the distance between them. The data were compared with the healthy group.
Peak activity increased after levodopa intake, indicating a reduction in bradykinesia. This feature partially correlates with clinicians' assessments and enhances the similarity of predictions by the MDS-UPDRS III scoring model to physician scores.
The results show the effectiveness of using sEMG and the number of peaks corresponding to the moments of muscle activation to assess bradykinesia.
帕金森病（PD）是一种常见的神经退行性疾病，其特征为静止性震颤、肌强直和运动迟缓。评估这些症状的严重程度通常使用运动障碍协会赞助的统一帕金森病评定量表修订版（MDS-UPDRS III）的第三部分，该评估依赖神经科医生的主观评价，这可能导致结果解释方面的挑战。为解决这一问题，可将表面肌电图（sEMG）纳入诊断。
本研究旨在寻找能够评估运动迟缓严重程度的特定sEMG模式。
本病例对照研究纳入了8例Hoehn & Yahr分期为2-3期的帕金森病患者和7名健康志愿者。在受试者进行MDS-UPDRS III的“手指轻敲”和“手部运动”测试时测量sEMG。在左旋多巴摄入前后均进行测试，以识别表明运动功能变化的模式。在测试过程中，我们观察了sEMG信号的峰值活动，该活动反映了参与运动执行的各个肌肉群的激活时刻。峰值活动通过sEMG信号最大极值的总数及其之间的距离来表征。将数据与健康组进行比较。
左旋多巴摄入后峰值活动增加，表明运动迟缓有所减轻。这一特征与临床医生的评估部分相关，并提高了MDS-UPDRS III评分模型预测与医生评分的相似性。
结果表明使用sEMG以及与肌肉激活时刻相对应的峰值数量来评估运动迟缓是有效的。
